Neurosyphilis diagnostic study of choice
Jump to navigation
Jump to search
|
Neurosyphilis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Neurosyphilis diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Neurosyphilis diagnostic study of choice |
|
Risk calculators and risk factors for Neurosyphilis diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamadmostafa Jahansouz M.D.[2]
Overview
The first step laboratory test when there is a clinical suspicious toward neurosyphilis is a venereal disease research laboratory test (VDRL) or rapid plasma reagin (RPR). Fluorescent treponemal antibody absorbed (FTA-ABS) test is the gold standard test for the diagnosis of neurosyphilis.
Diagnostic Study of Choice
Study of choice:
- The first step laboratory test when there is a clinical suspicious toward neurosyphilis is a venereal disease research laboratory test (VDRL) or rapid plasma reagin (RPR).
- Fluorescent treponemal antibody absorbed (FTA-ABS) test is the gold standard test for the diagnosis of neurosyphilis.[1]
- The fluorescent treponemal antibody absorbed (FTA-ABS) test should be performed when:
- A positive venereal disease research laboratory test (VDRL) or rapid plasma reagin (RPR) is detected in the patient.
The comparison table for diagnostic studies of choice for neurosyphilis
| Sensitivity | Specificity | |
|---|---|---|
| FTA-ABS | 96%[2] | |
| VDRL/RPR |
|
85% to 99%[2] |
References
- ↑ Lin LR, Fu ZG, Dan B, Jing GJ, Tong ML, Chen DT; et al. (2010). "Development of a colloidal gold-immunochromatography assay to detect immunoglobulin G antibodies to Treponema pallidum with TPN17 and TPN47". Diagn Microbiol Infect Dis. 68 (3): 193–200. doi:10.1016/j.diagmicrobio.2010.06.019. PMID 20846810.
- ↑ 2.0 2.1 2.2 2.3 Calonge N, U.S. Preventive Services Task Force (2004). "Screening for syphilis infection: recommendation statement". Ann Fam Med. 2 (4): 362–5. PMC 1466700. PMID 15335137.